Evogene Ltd (EVGN) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access EVGN Annual Cash Flow →
Looking at cash flow data from Evogene Ltd through Dec 31 2024 provides insight into Dec 31 2025's financial flexibility across reporting periods.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2025)
12 Months
0 0 0 (Dec 31 2024)
Operating Activities
Income-13.50
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Adjustments For Gain Loss On Disposals PropertyPlant And Equipment0.21
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.19
Amortisation Intangible Assets Other Than Goodwill-
Adjustments For Sharebased Payments-
Other Adjustments For Noncash Items-
Decrease Increase In Accrued Bank Interest-
Adjustments For Finance Income Cost-
Adjustments For Income Tax Expense-
Adjustments For Reconcile Profit Loss-
Adjustments For Increase Decrease In Employee Benefit Liabilities-
Adjustments For Increase Decrease In Other Operating Payables-
Adjustments For Increase Decrease In Deferred Income-
Adjustment For Increase Decrease In Changes In Asset And Liability Items-
Income Taxes Paid Classified As Operating Activities-
Adjustments For Decrease Increase In Inventories-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Adjustments For Decrease IncreaseIn Trade Account Receivable0.67
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-14.35
Discontinued operations0.00
Net Cash flow from Operating Activities-13.50
Investing Activities
Capital Expenditures0.14
Sale of Capital Items0.08
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceeds From Sales Of Investments Other Than Investments Accounted For Using Equity Method-
Purchase Of Marketable Securities-
Proceeds From Investment In Bank Deposits Net-
Withdrawal From Investment In Bank Deposits Net-
Proceeds From Short Term Bank Deposits-
Repayment Of Shortterm Bank Deposits-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net17.80
Discontinued operations0.00
Net Cash Flow from Investing Activities17.74
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-4.26
Increase Decrease In Cash And Cash Equivalents-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-6.60
Effect of exchange rate on cash flow0.02
Discontinued operations0.00
Free Cash Flow-13.29
Total Cash Flow15.30
4 historic quarters locked

Sign in to unlock the full Evogene Ltd cash flow history.

About Evogene Ltd Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 20-F filings and normalized by CSIMarket.

Source & verification

  • Form: 20-F (Period: 20251231)
  • Filed with the SEC: March 26, 2026
  • Source: zk2634882.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001178913-26-001767

Figures are derived from filed reports and may be restated. Historical data is subject to revision.